Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
PLoS One. 2013 May 3;8(5):e63118. doi: 10.1371/journal.pone.0063118. Print 2013.
The only approved pharmacological treatment for ischemic stroke is intravenous administration of plasminogen activator (tPA) to re-canalize the occluded cerebral vessel. Not only reperfusion but also tPA itself can induce an inflammatory response. Microglia are the innate immune cells of the central nervous system and the first immune cells to become activated in stroke. Neuroserpin, an endogenous inhibitor of tPA, is up-regulated following cerebral ischemia. To examine neuroserpin-dependent mechanisms of neuroprotection in stroke, we studied neuroserpin deficient (Ns(-/-))mice in an animal model of temporal focal ischemic stroke. Infarct size and neurological outcome were worse in neuroserpin deficient mice even though the fibrinolytic activity in the ischemic brain was increased. The increased infarct size was paralleled by a selective increase in proinflammatory microglia activation in Ns(-/-) mice. Our results show excessive microglial activation in Ns(-/-) mice mediated by an increased activity of tPA. This activation results in a worse outcome further underscoring the potential detrimental proinflammatory effects of tPA.
唯一被批准用于治疗缺血性中风的药理学方法是静脉内给予纤溶酶原激活物(tPA)以重新疏通闭塞的脑血管。不仅再灌注,而且 tPA 本身也可以引发炎症反应。小胶质细胞是中枢神经系统的固有免疫细胞,也是中风中最早被激活的免疫细胞。神经丝氨酸蛋白酶抑制剂(neuroserpin)是 tPA 的内源性抑制剂,在脑缺血后上调。为了研究神经丝氨酸蛋白酶抑制剂在中风中的神经保护作用的依赖机制,我们在局灶性短暂性缺血性中风的动物模型中研究了神经丝氨酸蛋白酶抑制剂缺乏(Ns(-/-))的小鼠。即使缺血性大脑中的纤维蛋白溶解活性增加,神经丝氨酸蛋白酶抑制剂缺乏的小鼠的梗死面积和神经功能结局仍更差。在 Ns(-/-)小鼠中,过度的小胶质细胞激活与 tPA 活性的增加相平行。这种激活导致更差的结果,进一步强调了 tPA 的潜在有害促炎作用。